Rep. Josh Gottheimer Buys Johnson & Johnson (NYSE:JNJ) Stock

Posted by James Quigley on Feb 12th, 2025

Representative Josh Gottheimer (D-New Jersey) recently bought shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Johnson & Johnson stock on January 24th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/31/2025.
Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 1/31/2025.
Sold $1,001 – $15,000 in shares of ICF International (NASDAQ:ICFI) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Mastercard (NYSE:MA) on 1/31/2025.
Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 1/30/2025.
Purchased $1,001 – $15,000 in shares of 3M (NYSE:MMM) on 1/30/2025.

Johnson & Johnson Trading Down 0.7 %

JNJ stock traded down $1.09 during midday trading on Wednesday, reaching $155.04. 2,179,008 shares of the company’s stock traded hands, compared to its average volume of 8,864,698. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The business has a 50-day moving average price of $147.48 and a two-hundred day moving average price of $156.01. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market capitalization of $373.27 billion, a P/E ratio of 23.32, a PEG ratio of 2.46 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the company posted $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.20%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is currently 74.59%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Citigroup cut their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Finally, Wolfe Research started coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 target price for the company. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $170.67.

View Our Latest Stock Analysis on JNJ

Institutional Investors Weigh In On Johnson & Johnson

Several hedge funds have recently modified their holdings of JNJ. AMF Tjanstepension AB lifted its holdings in shares of Johnson & Johnson by 14.2% in the third quarter. AMF Tjanstepension AB now owns 425,261 shares of the company’s stock valued at $68,985,000 after purchasing an additional 52,997 shares in the last quarter. Alpha Financial Partners LLC purchased a new stake in Johnson & Johnson in the 3rd quarter worth about $209,000. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $213,000. Brown Miller Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 2.3% in the 3rd quarter. Brown Miller Wealth Management LLC now owns 19,673 shares of the company’s stock valued at $3,188,000 after purchasing an additional 436 shares during the period. Finally, Mechanics Bank Trust Department boosted its holdings in shares of Johnson & Johnson by 0.5% during the third quarter. Mechanics Bank Trust Department now owns 57,568 shares of the company’s stock worth $9,329,000 after purchasing an additional 272 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.

Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.

Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.

Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About Johnson & Johnson

(Get Free Report)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.